Figure 6

Experimental manipulation of the cholinergic inflammatory pathway influences disease burden in preclinical models of RA and IBD. Surgical, genetic, or pharmacologic disruption of the CAP increases, while electrical and pharmacologic stimulation of the CAP decreases disease burden in preclinical models of RA and IBD.